Open an account

Kura Oncology

KURA · NASDAQ

$9.98+$0.62 (+6.62%)TodayMarket closed ·
Prev close $9.36

About KURA

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 260 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

Employees
260
Headquarters
San Diego, California
Listed
Nov 5, 2015
Sector
Health Care
Industry
Biotechnology
Website
kuraoncology.com

KURA key statistics

Market cap
832.67M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.77M
Volume
1.54M
Open price
$9.45
High today
$10.28
Low today
$9.28
52 Week high
$13.90
52 Week low
$7.36

Kura Oncology (KURA) at a glance

Kura Oncology (KURA) last traded at $9.98, with a market cap of 832.67M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.28 and $10.28. The current price is 7.5% above the day's low and 2.9% below its high.

Volume so far is 1.54M shares, in line with the average of 1.77M shares a day.

Over the past year Kura Oncology has ranged from $7.36 to $13.90, and now sits 40% of the way up that range.

Kura Oncology met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.77 per share against an estimate of -$0.8952.

The average analyst price target is $32.48, 225.5% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 15 analystsAvg $32.48
Low
$15.15
Now
$9.98
High
$79.80

KURA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 20.9% on average.

  1. Q3 FY24: reported -$0.63 per share against an estimate of -$0.6381
  2. Q4 FY24: reported -$0.22 per share against an estimate of -$0.6508
  3. Q1 FY25: reported -$0.66 per share against an estimate of -$0.3986
  4. Q2 FY25: reported -$0.75 per share against an estimate of -$0.4681
  5. Q3 FY25: reported -$0.85 per share against an estimate of -$0.8688
  6. Q4 FY25: reported -$0.92 per share against an estimate of -$0.4946
  7. Q1 FY26: reported -$0.83 per share against an estimate of -$0.6456
  8. Q2 FY26: reported -$0.77 per share against an estimate of -$0.8952

KURA news

  • Press releaseGlobe Newswire

    Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

  • Press releaseGlobe Newswire

    Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

  • Kura Oncology Q2 2026 Earnings Call Transcript

  • Vandana Singh

    Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

  • Press releaseGlobe Newswire

    Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

  • Press releaseGlobe Newswire

    Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

  • Press releaseGlobe Newswire

    Kura Oncology Reports Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity

Similar companies

Companies in the same industry as Kura Oncology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.